Form 4: Moderna President Stephen Hoge Reports Stock Transactions

Stephen Hoge, President of Moderna, reports the vesting of restricted stock units and subsequent tax withholding, resulting in changes to his beneficial ownership of company stock.

Summary

• On February 7, 2025, Stephen Hoge, President of Moderna, reported transactions involving Moderna's common stock.
• 523 restricted stock units vested and converted into common stock on a one-for-one basis.
• 281 shares were withheld to satisfy tax obligations related to the vesting of the restricted stock units at a price of $33.61.
• Following these transactions, Hoge directly owns 1,444,146 shares of Moderna common stock.
• Hoge also indirectly owns 4,116 shares through Valhalla, LLC and 151,933 shares through a trust for the benefit of his spouse and children.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Industry Context

This Form 4 filing is a routine disclosure of insider transactions, which are common for executives at publicly traded companies like Moderna. These filings are monitored by investors for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders at publicly traded companies, including pharmaceutical firms like Pfizer, BioNTech, and Johnson & Johnson.
• The vesting schedule of the restricted stock units (25% initially, then quarterly installments) is a common compensation structure used to incentivize long-term performance.
• Tax withholding practices related to RSU vesting are also standard across the industry.

Stakeholder Impact

• The transactions reported in this filing have a minimal direct impact on stakeholders.
• Shareholders may be interested in insider transactions as an indicator of management's confidence in the company.

Key Dates